Toshimasa Tsujinaka
Overview
Explore the profile of Toshimasa Tsujinaka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
179
Citations
3391
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nishikawa K, Koizumi W, Tsuburaya A, Suzuki M, Morita S, Fujitani K, et al.
Int J Clin Oncol
. 2024 Nov;
30(2):320-329.
PMID: 39585516
Background: Biweekly irinotecan plus cisplatin combination therapy (BIRIP) and irinotecan monotherapy (IRI) are both expectable second-line chemotherapy (SLC) options for treating advanced gastric cancer (AGC). Although many patients receiving SLC...
2.
Tamamori Y, Mori T, Tanaka A, Okada T, Tanaka S, Fumimoto Y, et al.
Surg Case Rep
. 2024 Aug;
10(1):185.
PMID: 39120680
Background: Suprapancreatic lymph node metastasis is one of the usual routes for gastric cancer. However, it is rare for the primary lesion to be found several years after resection of...
3.
Teranishi R, Takahashi T, Sato S, Sakurai K, Kishi K, Hosogi H, et al.
Gastric Cancer
. 2023 Dec;
27(2):355-365.
PMID: 38146035
Introduction: Contour maps enable risk classification of GIST recurrence in individual patients within 10 postoperative years. Although contour maps have been referred to in Japanese guidelines, their usefulness and role...
4.
Terashima M, Fujitani K, Yang H, Mizusawa J, Tsujinaka T, Nakamura K, et al.
Ann Gastroenterol Surg
. 2023 Sep;
7(5):741-749.
PMID: 37663970
Background: REGATTA trial failed to demonstrate the survival benefit of reduction gastrectomy in patients with advanced gastric cancer with a single non-curable factor. However, a significant interaction was found between...
5.
Kimura Y, Kawakami H, Tamura S, Fujitani K, Matsuyama J, Imamura H, et al.
Gastric Cancer
. 2023 Jun;
26(5):788-797.
PMID: 37335367
Background: S-1 plus docetaxel (DS) therapy followed by S-1 is the standard of care in Japan in postoperative adjuvant chemotherapy for stage III gastric cancer, but long-term survival and the...
6.
Ota T, Sakashita K, Sawada R, Seki K, Maeda H, Tanaka N, et al.
Surg Case Rep
. 2023 May;
9(1):71.
PMID: 37150760
Background: Alpha-fetoprotein-producing gastric cancer (AFPGC) is a rare type of aggressive gastric cancer (GC) with a dismal prognosis. We present a patient with AFPGC who achieved long-term survival through a...
7.
Boku S, Satake H, Ohta T, Mitani S, Kawakami K, Suzuki Y, et al.
Future Oncol
. 2022 Dec;
18(38):4153-4160.
PMID: 36475784
The V600E mutation accounts for approximately 5% of colorectal cancer (CRC) cases and is an extremely poor prognostic factor. However, there are no clear recommendations regarding first-line therapy for patients...
8.
Terazawa T, Kato T, Goto M, Ohta K, Satake H, Noura S, et al.
Oncologist
. 2022 Aug;
28(7):e565-e574.
PMID: 35947993
Background: We previously reported the response rate of a phase II OGSG1602 study on panitumumab in chemotherapy-naive frail or elderly patients with RAS wild-type unresectable colorectal cancer (CRC) [Terazawa T,...
9.
Endo S, Terazawa T, Goto M, Tanaka R, Kato T, Fujitani K, et al.
BMC Cancer
. 2022 Jul;
22(1):811.
PMID: 35870893
Background: Large type 3 and type 4 gastric cancers have extremely poor prognoses. To address this, neoadjuvant chemotherapy may be a promising approach. The phase III JCOG0501 study, conducted to...
10.
Nomura M, Kii T, Kawada J, Hirota M, Ohta T, Matsuyama J, et al.
Esophagus
. 2022 Jun;
19(4):711-716.
PMID: 35723843
Background: Fluorouracil (FU), platinum (PT), and taxane (TAX) therapy was the standard chemotherapy for esophageal squamous cell carcinoma (ESCC) before the era of anti-programmed death-1 antibodies. The aim of this...